Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids
NCT ID: NCT06317610
Last Updated: 2024-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2022-01-01
2024-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs
NCT05175326
Ovarian Cancer Radiomics Approach in CT Led Evaluation
NCT06817174
The Culture of Ovarian Cancer Organoids and Drug Screening
NCT04768270
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
NCT05290961
Individualized Precision Treatment Based on Ovarian Cancer Organoid Model
NCT05813509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI
biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients received biopsy or puncture to obtain tumor tissues or malignant effusion
* Patients voluntarily participated in the study and signed informed consent.
Exclusion Criteria
* No sufficient amount of tumor tissues or malignant effusion for organoids establishment.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chongqing University Cancer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dongling Zou, M.D.
Role: PRINCIPAL_INVESTIGATOR
Chongqing University Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CQGOG0206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.